Novartis CEO: Inclisiran Could Be Largest Medicine In NHS History
Pact To Make As-Yet-Unapproved Drug Widely Available
The Swiss major has been enthusing about its population-based agreement in the UK for the investigational gene silencing cholesterol lower and plans for similar schemes in other countries.
You may also be interested in...
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
The pricing of medicines may appear as a mystery to many; theories range from what the market will bear to prices being based on value. The Pink Sheet examines the role of two key players with influence in drug pricing in the UK – health technology assessment body NICE, which decides whether a product is value for money, and NHS England, which leads the tax-funded national health service in England and pays for new specialized drugs.
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.